885609-84-7

Basic information

• Product Name: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-
• Synonyms: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-;N-(2-broMo-5-fluorophenyl)pivalaMide;N-(2-BroMo-5-fluoro-phenyl)-2,2-diMethyl-propionaMide
• CAS NO: 885609-84-7
• Molecular Formula: C₁₁H₁₃BrFNO
• Molecular Weight: 274.1294232
• Mol File: 885609-84-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-(885609-84-7)
• EPA Substance Registry System: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-(885609-84-7)

Safety Data

• Hazardous Substances Data: 885609-84-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethylis used as an intermediate in the synthesis of pharmaceutical compounds for its potential to contribute to the development of new drugs. Its unique structural features, including the bromine and fluorine atoms, may enhance the pharmacological properties of the final products, such as improving binding affinity to target proteins or extending the duration of action.
Used in Agricultural Industry:
In agriculture, PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethylmay serve as an intermediate in the creation of agrochemicals, including pesticides or herbicides. PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-'s specific attributes could be leveraged to increase the effectiveness of these products or to reduce their environmental impact, although further research is required to confirm these potential applications.
Used in Organic Synthesis:
PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethylis utilized as a building block in organic synthesis for the preparation of a variety of organic compounds. Its structural components, including the bromine and fluorine substitutions, can be key in the formation of complex organic molecules with specific functionalities and applications in various industries.
Given the compound's potential applications, it is essential to conduct comprehensive studies to understand its behavior in different environments and its impact on human health and the ecosystem. This will ensure that PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethylcan be safely and effectively integrated into the intended applications.

Upstream product

• 1003-99-2 2-bromo-5-fluoroaniline 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 1372548-08-7 3-bromo-2-fluoro-6-iodo-5-(pyridin-2-yl)aniline 
• 1372548-06-5 2-(5-bromo-4-fluoro-2-iodo-3-nitrophenyl)pyridine 
• 1372548-10-1 N-(5-bromo-4-fluoro-7-(pyridin-2-yl)benzothiazol-2-yl)benzamide 
• 1202805-96-6 4-bromo-3-fluoro-6-(pyridin-2-yl)-2-nitroaniline 
• 1202805-95-5 N-[4-bromo-3-fluoro-6-(pyridin-2-yl)-2-nitrophenyl]-2,2-dimethylpropanamide 
• 1202805-94-4 N-[4-bromo-5-fluoro-2-(pyridin-2-yl)phenyl]-2,2-dimethylpropanamide 
• 1202805-93-3 N-[5-fluoro-2-(pyridin-2-yl)phenyl]-2,2-dimethylpropanamide 
• 1202805-45-5 N-[5-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2,2-dimethylpropanamide 

Relevant articles and documents

Palladium-catalyzed C(sp3)-H activation: A facile method for the synthesis of 3,4-dihydroquinolinone derivatives

3,4-Dihydroquinolinones were synthesized by the palladium-catalyzed, oxidative-addition-initiated activation and arylation of inert C(sp 3)-H bonds. Pd(OAc)2 and P(o-tol)3 were used as the catalyst and ligand, respectively, to improve the efficiency of the reaction. A further advantage of this reaction is that it could be performed in air. A relatively rare seven-membered palladacycle was proposed as a key intermediate of the catalytic cycle.

ANTIBACTERIAL COMPOUNDS

The present invention provides a compound of the following formula and salts thereof: Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS

The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonas spp., Acenetobacter spp., Moraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Ktycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Coryne bacterium, Bacillus spp., Enterobactericeae,' (E.coli, Klebsiella spp., Proteus spp.,etc. ) or any combination thereof Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections. (Formula)

CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Constrained compounds as CGRP-receptor antagonists

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.